RT @doctorRBC: 2 year extension study on Upadacitinib in active AS âï¸ASAS40 response maintained âï¸MRI SPARCC sc
Tweet Content
2 year extension study on Upadacitinib in active AS
⭐️ASAS40 response maintained
⭐️MRI SPARCC scores decreased and maintained
⭐️infections most common AE
⭐️NO MACE, lymphoma, skin cancer, GI perforations
Abs#924
#ACR21 #ACRBest
@RheumNow
https://t.co/725IRAOgtW https://t.co/FVUoCi6aoQ
Links
Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondyli…
https://bit.ly/3mSS1GJ
Show on Archive Page
On
Display in Search Results
On
PDQ
Off